Finance

Lists
ORKA:NASDAQ
Oruka Therapeutics Inc
$105.35
+0.34%
(+0.36) 1D
$105.35
0.00% (0.00)
After hours
Closed: Nov 13, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ORKA...
Open
$104.28
High
$106.87
Low
$101.56
Mkt. cap
7.15B
Avg. vol.
973.48K
Volume
679.68K
52-wk high
$115.52
52-wk low
$25.23
EPS
-$2.47
Beta
-0.38
Shares outstanding
67.82M
No. of employees
68
Open
$104.28
High
$106.87
Low
$101.56
Mkt. cap
7.15B
Avg. vol.
973.48K
Volume
679.68K
52-wk high
$115.52
52-wk low
$25.23
EPS
-$2.47
Beta
-0.38
Shares outstanding
67.82M
No. of employees
68
News stories
From web sources and news partners
About Oruka Therapeutics Inc
CEO-
Employees68
Founded2024
HeadquartersWestminster, Colorado, United States
SectorHealth Care
IndustryBiotechnology
Websiteorukatx.com
Analyst ratings
Based on 12 analysts giving stock ratings to ORKA in the past 3 months
Strong buy
Buy
12
Hold
0
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ORKA in the last 3 months.
Highest
Current $105.35
$200.00 (+89.84%)
Average
$153.60 (+45.80%)
Lowest
$105.00 (-0.33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Yee
UBS
Buy
Maintained
$130.00
+23.4%
11/10/2026
Yasmeen Rahimi
Piper Sandler
Buy
Maintained
$180.00
+70.9%
11/10/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$200.00
+89.8%
11/09/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Reiterated
$150.00
+42.4%
11/10/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$120.00
+13.9%
11/10/2026
Julian Harrison
BTIG
Buy
Reiterated
$151.00
+43.3%
11/09/2026
Etzer Darout
Barclays
Buy
Maintained
$160.00
+51.9%
11/10/2026
David Risinger
Leerink Partners
Buy
Reiterated
-
-
10/27/2026
Martin Fan
Wedbush
Buy
Reiterated
$165.00
+56.6%
10/27/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$165.00
+56.6%
10/27/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
$105.00
-0.3%
10/26/2026
David Nierengarten
Wedbush
Buy
Maintained
$165.00
+56.6%
09/24/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$175.00
+66.1%
09/23/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/26/2026
Roger Song
Jefferies
Buy
Maintained
$133.00
+26.2%
08/11/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
$200.00
+89.8%
08/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27.64M
29.14M
43.26M
53.70M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.79M
7.29M
6.85M
8.44M
Operating expense
34.43M
36.43M
50.11M
62.14M
Total operating expenses
34.43M
36.43M
50.11M
62.14M
Operating income
-34.43M
-36.43M
-50.11M
-62.14M
Other non operating income
-1.00K
8.00K
4.00K
5.00K
EBT including unusual items
-29.58M
-31.82M
-41.21M
-49.96M
EBT excluding unusual items
-29.58M
-31.82M
-41.21M
-49.96M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-29.58M
-31.82M
-41.21M
-49.96M
Net profit margin
-
-
-
-
Earnings per share
-0.45
-0.48
-0.55
-0.63
Interest and investment income
4.85M
4.61M
8.90M
12.17M
Interest expense
-
-
-
-
Net interest expenses
4.85M
4.61M
8.90M
12.17M
Depreciation and amortization charges
-
-
-
-
EBITDA
-34.40M
-36.39M
-50.06M
-62.09M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps